Signet Jewelers diskutieren
Signet Jewelers
WKN: A0Q9SE / Symbol: SIG / Name: Signet / Aktie / Spezialhandel / Small Cap /
73,78 €
0,95 %
Signet Jewelers Limited (NYSE: SIG) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $119.00 price target on the stock, up previously from $93.00.
Ratings data for SIG provided by MarketBeat
Signet Jewelers Limited (NYSE: SIG) had its price target raised by analysts at Wells Fargo & Company from $100.00 to $110.00. They now have an "overweight" rating on the stock.
Ratings data for SIG provided by MarketBeat
Signet Jewelers Limited (NYSE: SIG) had its price target raised by analysts at Wells Fargo & Company from $110.00 to $120.00. They now have an "overweight" rating on the stock.
Ratings data for SIG provided by MarketBeat
Signet Jewelers Limited (NYSE: SIG) had its price target lowered by analysts at UBS Group AG from $138.00 to $134.00. They now have a "buy" rating on the stock.
Ratings data for SIG provided by MarketBeat
Signet Jewelers Limited (NYSE: SIG) had its price target raised by analysts at UBS Group AG from $128.00 to $152.00. They now have a "buy" rating on the stock.
Ratings data for SIG provided by MarketBeat
Signet Jewelers Limited (NYSE: SIG) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for SIG provided by MarketBeat
Signet Jewelers Limited (NYSE: SIG) had its price target raised by analysts at Wells Fargo & Company from $120.00 to $125.00. They now have an "overweight" rating on the stock.
Ratings data for SIG provided by MarketBeat
Signet Jewelers Limited (NYSE: SIG) had its "buy" rating re-affirmed by analysts at Citigroup Inc.. They now have a $119.00 price target on the stock.
Ratings data for SIG provided by MarketBeat
Signet Jewelers Limited (NYSE: SIG) had its price target lowered by analysts at Wells Fargo & Company from $125.00 to $105.00. They now have an "overweight" rating on the stock.
Ratings data for SIG provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Mersana Therapeutics diskutieren